Evidence Based Hair: Recent Episodes
Dr Jeff Donovan
Evidence based hair is a weekly podcast hosted by Dr Jeff Donovan, a Canadian dermatologist and hair specialist. Each week, Dr. Donovan highlights recently published hair loss research from around the world.
Welcome to the final episode of the Evidence-Based Hair Podcast for 2024, hosted by Dr. Jeff Donovan, a leading dermatologist and hair loss specialist. In this episode, Dr. Donovan dives into the complex relationship between alopecia areata and cardiovascular risk, exploring recent studies that offer conflicting conclusions.
Dr. Donovan reviews a notable study published in JAD International, which leverages the All of Us Research Program database to investigate whether alopecia areata patients are at increased risk for cardiovascular diseases. The study reveals intriguing findings, suggesting a potential link with chronic kidney disease and hyperlipidemia, but not with heart disease.
As the podcast unfolds, Dr. Donovan discusses the broader implications of these findings, the need for long-term studies, and the ongoing debate in the medical community. He also invites listeners to a special event celebrating the top 20 studies of 2024.
Join Dr. Donovan as he navigates through the complexities of hair loss research, empowering practitioners and patients alike with evidence-based insights. For more information on the Donovan Hair Academy's programs, visit their website.
STUDIES REFERENCED IN THIS EPISODE
Ambika Nohria, Jill T Shah, Deesha Desai, Lina Alhanshali, Jenne Ingrassia, Alisa Femia, Michael Garshick, Jerry Shapiro, Kristen I Lo Sicco. Alopecia areata and cardiovascular comorbidities: A cross-sectional analysis of the All of Us research program. JAAD Int. 2024 Apr 8:16:46-48. doi: 10.1016/j.jdin.2024.03.024. eCollection 2024 Sep.
Lee et al. Alopecia areata is not a risk factor for heart diseases: A 10-year retrospective cohort study. PLoS One. 2021.
Conic RRZ et al. Prevalence of cardiac and metabolic diseases among patients with alopecia areata. JEADV 2021
Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist Dr. Jeff Donovan. In this episode, Dr. Donovan explores a groundbreaking study published in the journal Curious, highlighting the effectiveness of the JAK1 inhibitor, upadacitinib, in treating recalcitrant dissecting cellulitis of the scalp.
Dissecting cellulitis, a challenging form of scarring alopecia, often affects males and presents with debilitating symptoms. While traditional treatments like isotretinoin and antibiotics offer relief for some, they aren't always effective. The study discusses a case where upadacitinib brought significant improvement after conventional options were exhausted.
Dr. Donovan provides a comprehensive overview of the study, emphasizing the potential of JAK inhibitors as third-line treatments in managing persistent dissecting cellulitis. He also shares insights on the broader implications for future research and treatment strategies.
Join Dr. Donovan next week for an analysis of a study on alopecia areata and cardiovascular comorbidities, and don't miss the annual "Top 20 of 2024" event on December 30th. For more information about the Donovan Hair Academy's programs, visit their website.
STUDY REFERENCED IN THIS EPISODE
Zahidul Islam, Michelle Toker, Isha M Gandhi, Ariel Sher, Kristina Campto. Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib. Cureus . 2024 Jan 16;16(1):e52377. doi: 10.7759/cureus.52377. eCollection 2024 Jan.
Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist Dr. Jeff Donovan. In this episode, we delve into an intriguing study titled "Dupilumab Induces Hair Regrowth in Pediatric Alopecia Areata," which explores the potential of dupilumab as a treatment for children suffering from both alopecia areata and atopic dermatitis.
Dr. Donovan discusses the study's findings, highlighting how dupilumab has shown promise in improving hair growth in this unique patient population. With a good safety profile, dupilumab emerges as a viable option alongside JAK inhibitors for managing these conditions. The episode also covers the study's methodology and results, emphasizing the significant reduction in SALT scores among the participants.
Join Dr. Donovan as he shares insights into the complexities of treating pediatric alopecia areata and the potential of dupilumab to offer new hope for patients and clinicians alike. Stay tuned for the next episode, where we'll explore the use of upadacitinib in managing dissecting cellulitis.
STUDY REFERENCED IN THIS EPISODE
Eden David, Neda Shokrian, Ester Del Duca, Marguerite Meariman, Jacob Glickman, Sabrina Ghalili, Seungyeon Jung, Kathryn Tan, Benjamin Ungar, Emma Guttman-Yassky. Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study. Arch Dermatol Res . 2024 Jul 23;316(7):487. doi: 10.1007/s00403-024-03225-4.
Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is committed to educating both the public and practitioners about hair loss through comprehensive training programs.
In this episode, Dr. Donovan dives into an intriguing study published in the International Journal of Dermatology, which examines the use of topical metformin 10% cream in treating Central Centrifugal Cicatricial Alopecia (CCCA). This scarring alopecia primarily affects Black women and is often underdiagnosed. The study highlights a case where topical metformin showed promise in hair regrowth for a patient unresponsive to traditional treatments.
Dr. Donovan discusses the potential of topical metformin as a second-line treatment option alongside oral metformin, PRP, and JAK inhibitors, while emphasizing the importance of first-line treatments such as steroid injections and topical steroids. He also addresses the challenges of compounding metformin in various formulations, which can affect its efficacy.
Stay tuned for next week's episode, where Dr. Donovan will explore new research on alopecia areata and dupilumab. Join us as we continue to unravel the complexities of hair loss and discover innovative treatments that could benefit patients worldwide.
STUDY REFERENCED IN THIS EPISODE
Bárbara Vieira Granja et al. Treatment of central centrifugal cicatricial alopecia with topical metformin 10% cream: case report and literature review. Int J Dermatol . 2024 Jun 23. doi: 10.1111/ijd.17345. Online ahead of print
Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating the public and training practitioners in the complex field of hair loss.
In this episode, Dr. Donovan delves into a fascinating study from JAMA Dermatology that examines the effects of low-dose metformin on Central Centrifugal Cicatricial Alopecia (CCCA). The study reveals intriguing changes in gene expression that could offer new insights into treating this underdiagnosed condition, primarily affecting black women.
Despite the study's small size and retrospective nature, the findings highlight metformin's potential role in modifying pathways related to scarring alopecia and hair growth. Dr. Donovan emphasizes the need for further research to understand metformin's efficacy and optimal dosing for CCCA patients.
Join us next week as Dr. Donovan discusses the use of metformin cream in CCCA, continuing the exploration of innovative treatments in hair loss management. Stay informed and empowered to engage in meaningful discussions with hair loss practitioners.
STUDY REFERENCED IN THIS EPISODE
Aaron Bao et al. Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia. JAMA Dermatol . 2024 Sep 4:e243062. doi: 10.1001/jamadermatol.2024.3062. Online ahead of print.
Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by Dr. Jeff Donovan, dermatologist and hair loss specialist. In this episode, Dr. Donovan delves into a fascinating study published in the Journal of the American Academy of Dermatology and Venereology, which explores the potential association between hair loss and the use of popular weight loss medications, such as semaglutide and terzepatide.
Dr. Donovan discusses the methodology and findings of the study, which utilized the FDA Adverse Event Reporting System to analyze reports of alopecia linked to these drugs. The episode highlights the importance of post-marketing research in uncovering side effects not initially apparent in clinical trials.
Join Dr. Donovan as he explains the statistical technique of disproportionality analysis used in the study, and its implications for understanding the potential hair loss risks associated with these medications. The episode also emphasizes the need for further research to better understand the timing, mechanism, and prevalence of hair loss among different patient groups.
Stay tuned for next week's episode, where Dr. Donovan will explore the effects of metformin on central centrifugal cicatricial alopecia, based on a recent study in JAMA Dermatology. Thank you for tuning in and supporting the Evidence-Based Hair Podcast, dedicated to advancing education and research in the complex world of hair loss.
STUDIES REFERENCED IN THIS EPISODE
Hannah Godfrey, Zachary Leibovit-Reiben, Patrick Jedlowski, Rebecca Thiede. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol . 2024 Jun 24. doi: 10.1111/jdv.20197. Online ahead of print.
Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating both the public and hair loss practitioners about the complexities of hair loss.
In this episode, Dr. Donovan delves into a fascinating study from JAAD Case Reports, which explores the potential benefits of the diabetes drug terzepatide for treating androgenetic alopecia. This groundbreaking case report suggests that medications targeting insulin resistance could offer new strategies for hair growth.
Join Dr. Donovan as he breaks down the study, discusses the implications of using GLP-1/GIP receptor agonists for hair loss, and highlights the importance of understanding the metabolic connections to androgenetic alopecia. Discover how these findings could pave the way for novel treatment approaches and what it means for patients worldwide.
Whether you're a practitioner, researcher, or someone affected by hair loss, this episode provides insightful perspectives on the future of hair loss treatment. Tune in to learn more about the potential of terzepatide and similar medications in addressing hair loss challenges.
STUDY REFERENCED
Gordon E, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep . 2024 Jun 11:50:123-125. doi: 10.1016/j.jdcr.2024.06.001. eCollection 2024 Aug.
Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. In this episode, we delve into a crucial study exploring the unexpected side effects of steroid injections used in treating alopecia areata, particularly focusing on central serous chorioretinopathy (CSC). This condition, characterized by fluid accumulation beneath the retina, can lead to vision problems and retinal detachment.
Dr. Donovan reviews a compelling paper published in JAAD Case Reports, highlighting two cases where patients developed CSC after receiving steroid injections for hair loss. The episode emphasizes the importance of recognizing blurry vision as a potential warning sign and the need for immediate consultation with an eye specialist.
Join us as we discuss the implications of this study for hair loss specialists and the necessity of ongoing research to better understand the risks associated with long-term steroid use. Stay tuned for next week's episode, where we'll explore the role of tirzepatide in androgenetic hair loss treatment.
STUDIES REFERENCED IN THIS EPISODE
Deesha Desai, Ambika Nohria, Lina Alhanshali, Michael Buontempo, Kristen I Lo Sicco, Craig Fern, Jerry Shapiro. Central serous chorioretinopathy after scalp and eyebrow intralesional triamcinolone acetonide injections: Report of two cases. JAAD Case Rep . 2024 Jul 14:51:86-91. doi: 10.1016/j.jdcr.2024.06.034. eCollection 2024 Sep.
Welcome to another insightful episode of the Evidence-Based Hair Podcast with Dr. Jeff Donovan, a dermatologist and hair loss specialist. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating the public and practitioners about hair loss through comprehensive training programs.
In this episode, Dr. Donovan explores a fascinating study from the Brazilian Annals of Dermatology, focusing on the trichoscopic features of alopecia neoplastica caused by breast cancer metastases. Alopecia neoplastica, a type of hair loss linked to neoplastic processes, can sometimes resemble alopecia areata, but presents with distinct trichoscopic patterns. Dr. Donovan discusses the study's findings on the blood vessel patterns and color variations that are key indicators of this condition.
Join us as we delve into the clinical case of a patient with metastatic breast cancer presenting with alopecia neoplastica. Discover the significance of early detection and how trichoscopy can aid in diagnosing and managing this complex form of hair loss.
Tune in next week as we explore the rare side effect of central serous chorioretinopathy from steroid injections, and continue our journey of empowering clinicians and patients through education.
STUDIES REFERENCED IN THIS EPISODE
Bruno Simão Dos Santos, Eduardo César Diniz Macêdo, Bruna Nascimento Arruda Scabello, Patrícia Porto de Oliveira Grossi, Neusa Yuriko Sakai Valente. Dermoscopy of neoplastic alopecia secondary to cutaneous metastasis from breast carcinoma. An Bras Dermatol. 2024 Sep-Oct;99(5):742-745. doi: 10.1016/j.abd.
Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is committed to educating both the public and hair loss practitioners through comprehensive programs like the Evidence-Based Hair Fellowship (EBHF).
In this episode, Dr. Donovan delves into a compelling case report from JAAD Case Reports that explores the use of diphencyprone (DPCP) for treating alopecia areata during pregnancy. Traditionally contraindicated in pregnancy, DPCP is a topical treatment that induces an allergic reaction on the scalp to promote hair regrowth in patients with alopecia areata. Dr. Donovan discusses a unique case where a patient opted to continue DPCP treatment during her pregnancies, resulting in minimal hair loss without any adverse effects on her pregnancies or babies.
Dr. Donovan emphasizes the significance of this study in contributing to the limited data available on DPCP use during pregnancy. While the findings are promising, he cautions that more research is needed before making broad recommendations for DPCP use during pregnancy.
Join Dr. Donovan next week too as he explores the trichoscopy of alopecia neoplastica from breast cancer in another enlightening episode of the Evidence-Based Hair Podcast. Don't miss this opportunity to expand your knowledge and engage in meaningful discussions about hair loss treatment and research.
STUDIES REFERENCED IN THIS EPISODE:
Desai DD et al. Use of diphenylcyclopropenone for alopecia areata treatment during pregnancy. JAAD Case Rep. 2024 Apr 19:48:88-89.
Berth-Jones et al. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venerol 1994; 74: 312-3.
Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating both the public and practitioners about hair loss through comprehensive training programs like the Evidence-Based Hair Fellowship.
In this episode, Dr. Donovan delves into the critical topic of JAK inhibitors and their safety during pregnancy. He explores a pivotal study published in Drug Safety that examines pregnancy outcomes in patients treated with Upadacitinib, a JAK inhibitor used for various inflammatory disorders, including alopecia areata.
The episode provides an in-depth analysis of data from clinical trials and post-marketing reports, highlighting the impact of JAK inhibitors on pregnancy outcomes, such as congenital anomalies and live births. Dr. Donovan discusses the importance of understanding the safety of these medications in pregnancy and emphasizes the need for more research in this area.
Listeners will gain valuable insights into the complexities of managing hair loss treatments during pregnancy and the challenges faced by patients and clinicians alike. Dr. Donovan also shares promising findings and case studies involving other JAK inhibitors, offering a comprehensive overview of the current landscape and future directions in this field.
Join us for this informative episode as Dr. Donovan addresses a pressing concern in the world of hair loss and pregnancy, providing expert analysis and guidance for both practitioners and patients.
REFERENCES
Uma Mahadevan et al. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Saf . 2024 Oct;47(10):1039-1049. doi: 10.1007/s40264-024-01454-0. Epub 2024 Jul 15.
Megan E B Clowse et al. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf . 2016 Aug;39(8):755-62. doi: 10.1007/s40264-016-0431-z.
Mahadevan U et al. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Inflamm Bowel Dis. 2018 Nov 29;24(12):2494-2500. doi: 10.1093/ibd/izy160.
Welcome back to Season 8 of the Evidence-Based Hair Podcast! I'm Dr. Jeff Donovan, a dermatologist and hair loss specialist. Join me each week as I review groundbreaking studies that are transforming our understanding of hair loss and influencing clinical practices.
This season, we'll delve into a variety of compelling topics including hair loss medications during pregnancy, JAK inhibitors like upadacitinib and baricitinib, and the use of terzepatide and metformin. We'll also explore conditions such as alopecia areata, androgenetic hair loss, CCCA, and dissecting cellulitis, and discuss their links to heart disease, thyroid disease, and breast cancer.
Episodes will be released every Monday, and you can also find video presentations on our Donovan Medical YouTube channel. Thank you for your continued interest, and we look forward to another exciting season!
Welcome back to the Evidence-Based Hair Podcast! This episode continues our June theme on JAK inhibitors, focusing on their topical use for treating frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP).
We'll delve into a groundbreaking study by Dr. Maryanne Senna and colleagues from Boston, examining the effectiveness and side effects of topical 2% tofacitinib for FFA and LPP. The study's results provide encouraging data, showing that about 31.6% of patients experienced improvement, and 60.5% saw disease stabilization.
Join us as we explore the potential of topical JAK inhibitors in managing scarring alopecia, their practical applications, and the implications for future treatment protocols. Don't miss our insightful discussion on this emerging therapy and how it could transform patient care.
Next month, we'll shift gears to discuss spironolactone and its role in treating androgenetic hair loss in women. Stay tuned!
STUDIES REFERENCED IN THIS EPISODE
Li-Chi Chen, Chino Ogbutor, Kristen J Kelley, Maryanne M Senna. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024 Jun;90(6):1260-1262. doi: 10.1016/j.jaad.2024.01.060. Epub 2024 Feb 2.
Yang C.C., Khanna T., Sallee B., Christiano A.M., Bordone L.A.: Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther 2018; 31:
Moussa A., Bhoyrul B., Asfour L., Kazmi A., Eisman S., Sinclair R.D.: Treatment of lichen planopilaris with baricitinib: a retrospective study. J Am Acad Dermatol 2022; 87: pp. 663-666.
Plante J., Eason C., Snyder A., Elston D.: Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol 2020; 83: pp. 1487-1489.
Welcome back to another episode of the Evidence-Based Hair Podcast. This week, we continue our June theme of JAK inhibitors, focusing on the use of topical JAK inhibitors for treating frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP).
In this episode, we delve into a significant study by Dr. Maryanne Senna and colleagues from Boston, exploring the effectiveness and side effects of topical 2% tofacitinib for LPP and FFA. The study, involving 41 patients, provides valuable statistics on improvement and stabilization rates, offering practical insights for clinical application.
We discuss the potential of topical JAK inhibitors, given their less systemic absorption compared to oral forms, and their specific relevance to scarring alopecia where inflammation is closer to the skin's surface. Despite some challenges with compounded topical formulations, the study's promising results highlight a third of patients showing improvement and over 60% achieving disease stabilization.
Join us as we wrap up our June series on JAK inhibitors and prepare for July, where we'll focus on the antiandrogen spironolactone and its use in androgenetic hair loss in women.
Thank you for tuning in, and I look forward to our next discussion on the Evidence-Based Hair Podcast.
STUDY REFERENCED
Li-Chi Chen, Chino Ogbutor, Kristen J Kelley, Maryanne M Senna. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024 Jun;90(6):1260-1262. doi: 10.1016/j.jaad.2024.01.060. Epub 2024 Feb 2.
Welcome to another episode of the Evidence-Based Hair Podcast. In this episode, Dr. Donovan delves into an insightful study by Zhao and colleagues, published in the Journal of the European Academy of Dermatology and Venereology, titled "Baricitinib Therapy for Pediatric Patients with Severe Alopecia Areata."
This episode continues the June series dedicated to JAK inhibitors. Dr. Donovan highlights the increasing global use of these medications for treating severe alopecia areata, including the recent approvals of baricitinib and ritlicitinib.
The featured study examines the effectiveness and safety of baricitinib in treating children with severe alopecia areata, focusing on a small group of 10 patients aged between under two years to 13 years. The results reveal promising regrowth and mild side effects, underscoring the potential of baricitinib for younger patients.
Dr. Donovan discusses the broader implications of these findings, including the likelihood of future approvals for younger age groups and the importance of long-term safety data. He emphasizes the need for ongoing research and real-world studies to better understand the prolonged effects of JAK inhibitors.
Join Dr. Donovan next week for the final episode of the June series, where he will explore a study on the use of topical tofacitinib for treating lichen planopilaris and frontal fibrosing alopecia.
Welcome back to another episode of the Evidence-Based Hair Podcast! In this episode, we delve into a fascinating study on the use of generic tofacitinib for treating alopecia areata.
This study, published in the Archives of Dermatologic Research, explores the effectiveness and safety of generic tofacitinib. With the recent availability of this cost-effective alternative in Canada, the study provides valuable insights into whether switching from brand name options (Xeljanz) is a viable choice for patients.
The retrospective study included 20 patients with advanced alopecia areata, and the results were promising. A significant number of patients experienced noticeable improvements in hair regrowth, with low incidence of side effects. This episode discusses the study's findings and the broader implications for treatment options in alopecia areata.
Join me as we explore how this study might change the landscape of hair loss treatment and what it means for patients and practitioners alike. Don't miss next week's episode, where we'll discuss the use of baricitinib in young children.
STUDY REFERENCED
Jian J et al. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study. Arch Dermatol Res. 2024 May 11;316(5):154. doi: 10.1007/s00403-024-02879-4.
In this June series of the podcast, we focus on JAK inhibitors. This episode kicks off with a detailed review of an Italian study published in Expert Opinion in Drug Safety, which examines the incidence and management of infections in patients with alopecia areata treated with JAK inhibitors. Dr. Donovan discusses the findings, emphasizing that about one in three patients on JAK inhibitors may develop infections, highlighting the need for careful monitoring and potential treatment pauses.
Additionally, Dr. Donovan reviews a study from New York in Archives of Dermatologic Research, which reveals low vaccination rates among patients with immune-mediated diseases on biologics and JAK inhibitors. The study underscores the importance of pre-treatment vaccinations to mitigate infection risks.
Join us next week as we explore the efficacy and cost benefits of generic tofacitinib in managing alopecia areata, part of our ongoing series on JAK inhibitors. Stay tuned for more insights and expert analysis on the Evidence-Based Hair Podcast.
STUDIES REFERENCE IN THIS WEEK'S EPISODE
Giacomo Caldarola et al. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment. Expert Opin Drug Saf. 2024 May 8:1-5.
Hren MG and Khattri S. Low rates of vaccination among atopic dermatitis, alopecia areata, psoriasis, and psoriatic arthritis patients on biologics. Arch Dermatol Res. 2024 May 25;316(6):285
In this episode, Dr. Jeff Donovan, a dermatologist and hair loss specialist, examines the effect of topical minoxidil in enhancing beard hair growth in men
Dr. Donovan focuses on a study published in Sage Open Medicine Case Reports titled, "Facial Hair Enhancement with Minoxidil and Off-Label Use". This study highlights the impact of using topical minoxidil for beard hair growth. As a subject frequently questioned by men worldwide, understanding the benefits, side effects, and the result of its use is vital.
A noteworthy part of this study was that it compared the use of topical minoxidil by two identical twins. Only one of the twins applied minoxidil on his face, and as early as the first month, finer, lighter-colored hairs appeared on his beard and mustache. He experienced hair shedding for a few months but still showed overall improvement in hair density and count after using minoxidil for 16 months.
Despite mild side effects such as skin dryness and hypertrichosis on ears and forehead, as well as increased body hair in other areas, the study shows that minoxidil can be an effective strategy for males wishing to enhance their facial hair. The patient in the case report switched to topical minoxidil foam due to dry flakiness caused by the solution, suggesting that the foam might be a preferable choice for some users.
To sum up, this 16-month-long study provides valuable insights on the potential effectiveness of using minoxidil for beard growth. Despite the side effects and need for more long-term data, the results suggest that it is a reasonably safe and potentially helpful approach for those who desire to improve their facial hair density.
In this episode, we will dive into fascinating recent studies about the side effects of Minoxidil, a widely-known medication for hair loss treatment.
This podcast highlights new research regarding what Dr. Donovan calls "the OMAHA effect" (ORAL MINOXIDIL ALCOHOL HANGOVER ASSOCIATION), the surprising association between oral minoxidil use and exacerbated alcohol hangover symptoms. This phenomenon challenges previous conceptions in the medical field and warrants further investigation into potential implications for patients using oral Minoxidil.
However, though intriguing, the data about the OMAHA effect lacks detailed and quantitative information about the patients involved and their experiences. This calls for more precise and extensive research on the matter. Dr. Donovan emphasizes the need to gather more information before this knowledge can lead to changes in medical practice.
Moving forward, the episode also examines another study analyzing the association between topical Minoxidil and hair discoloration. This study equips you with more concrete data, reporting that about one-fourth of patients using Minoxidil perceive that the treatment has led to their hair graying. Despite the product monograph advising patients to stop minoxidil use when hair discoloration is noticed, the podcast argues that this abrupt termination might not be practical as patients risk losing the new hair growth achieved with Minoxidil when they stop the treatment.
Overall, this discussion underscores how hair graying and discoloration, like hair loss, also significantly impacts individuals' lives. As researchers dedicate more attention to understanding these issues, expect more practical guidelines and breakthroughs in combatting them.
Join Dr. Donovan every week for insightful discussions about ground-breaking studies relevant to hair loss and its treatment. Stay tuned for our next episode where we look into topical Minoxidil use for beard growth.
In this episode, we dive into a thought-provoking study by Sanfilippo and Friedman, "Survey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Hair Loss".
The study provides valuable insights into the perceptions of practitioners on oral minoxidil, an increasingly popular option for treating hair loss.
We discuss the results of this survey and compare it with previous studies, shedding light not only on the effectiveness of oral minoxidil but also on the practitioners' comfort level in prescribing it and patients' satisfaction with its results.
The pulse of the global community and the evidence provided by well-conducted studies play a significant role in shaping our understanding of oral minoxidil. There's a critical need for long-term evaluations and more comprehensive studies to establish its effects and side effects over years of use.
Stay tuned for more in-depth discussions as we continue to explore the realm of hair loss treatments.
And don't forget, if you want to immerse yourself in the study of hair loss and acquire advanced clinical and problem-solving skills, consider applying for a training position in the Evidence-Based Hair Fellowship, the world's most comprehensive program for physicians and allied health professionals.
In this episode of the Evidence-Based Hair Podcast hair loss specialist Dr. Jeff Donovan breaks down the findings of a recent study comparing oral minoxidil and topical minoxidil in the treatment of male androgenetic alopecia. Published in JAMA Dermatology, the study challenged popular opinions by revealing similar performance between the two types of minoxidil, putting a spotlight on the importance of robust evidence from randomized controlled trials.
Interestingly, Dr. Donovan examined the historical usage of oral minoxidil, once a blood pressure medication, in treating hair loss and the subsequent need for more rigorous studies to solidify its effectiveness. The episode also covers the surprising conclusion that oral minoxidil did not significantly outperform its topical counterpart, contrary to what the mainstream assumes.
Diving deeper into the debate, Dr. Donovan explored differing perspectives derived from the Pantchprateep et al and Penha et al studies of oral minoxidil. Where the Panchaprateep et al study suggested that all patients saw some improvement, the Penha et al study showed that not all participants experienced the same positive results.
In an in-depth examination of the 'Oral Minoxidil versus Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial', the potential side effects, including minor adverse effects of both treatments were also discussed. While not definitive in recommending one treatment over the other, the episode sparks stimulating discussions around the efficacy of oral minoxidil, its comparison to topical minoxidil, and the potential of randomized controlled trials in determining the optimal treatment for male androgenetic hair loss.
STUDIES REVIEWED IN THIS EPISODE
Penha MA et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol . 2024 Apr 10:e240284. doi: 10.1001/jamadermatol.2024.0284. Online ahead of print
Panchaprateep et al. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther. 2020 Dec;10(6):1345-1357
This episode is dedicated to a fascinating subject – drug-induced alopecia areata. In addition to genetic factors, alopecia areata is also influenced by environmental factors such as infections and medications. In this episode, Dr Donovan highlights two studies: “A Cross-Sectional Analysis of Medications Used by Patients Reporting Alopecia Areata on the FDA Adverse Events Reporting System” by Ravapati et al and “Drug-Induced Alopecia Areata: A Systematic Review” by Ezemma et al. These studies present an intensive exploration of drugs possibly causing alopecia areata.
Studies show that monoclonal antibodies are common culprits, and reports of drug-induced alopecia areata are rising every over time.
Surprisingly, it has been observed that the onset of drug-induced alopecia areata could be delayed by as much as a year. Also, patients who discontinued the alleged drug stimulating alopecia areata experienced regrowth of hair, while those who didn't, failed unless treated.
Email is info@donovanhairacademy.com or visit our website www.donovanhairacademy.com.
Thank you all for joining. See you next week!
Welcome to a new episode of the Evidence-Based Hair Podcast, where we discuss some questions surrounding the relationship between dupilumab and lymphoma. This episode dives deep into a study by Hasan and colleagues that explores the fascinating and somewhat controversial relationship between Dupilumab, a drug often used to treat atopic dermatitis patients with alopecia areata, and an increased risk of Cutaneous T-Cell Lymphoma (CTCL). Despite its potential benefits, does Dupilumab truly cause CTCL, or does it simply unmask the disease in patients who were previously misdiagnosed?
Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.
While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it.
As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL. Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.
donovanmedical Edited•Season 7 of the Evidence Based Hair Podcast has started. This week I review several fascinating studies: The podcast can be accessed wherever you listen to your podcasts or via the DonovanMedical youtube channel.
REFERENCES IN THIS EPISODE Hasan I et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566-8. doi: 10.1016/j.jaad.2024.03.039. Online ahead of print.
Jfri A et al. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review. J Am Acad Dermatol . 2023 May;88(5):1164-1166. doi: 10.1016/j.jaad.2022.12.001. Epub 2022 Dec 5.
Espinosa ML et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol . 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27.
This is a recording from the live webinar was conducted live December 13, 2023. This is an annual event that is held every year in mid-December celebrating the top hair research studies.
DERMATOPATHOLOGY
Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.
ANDROGENETIC ALOPECIA
Gupta AK et al.The relative efficacy of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. J Cosmet Dermatol. 2023 Jun 29
Jimenez-Cauhe J et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
ALOPECIA AREATA
Gandhi et al.The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata. Dermatol Ther (Heidelb). 2023 Jan;13(1):285-298.
Li SJ et al. Experiencing Workplace Bullying in Patients with Alopecia Areata: A Cross-Sectional Survey Study. Skin Appendage Disord. 2023 Aug;9(4):258-261
Kazmi A et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.
King B et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023 May 6;401(10387):1518-1529.
George P et al. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023
TELOGEN EFFLUVIUM
Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.
TINEA CAPITIS
Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.
COSMETIC DERMATOLOGY
Landau M et al. Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37
FOLLICULITIS DECALVANS
Matard B et al. Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association. Br J Dermatol 2022 Dec;187(6):1026-1028.
DISCOID LUPUS
Fredeau L et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol. 2023 Mar;88(3):551-559.
DISSECTING CELLULITIS
Cajas-Garcia MS et al. Distinct presentations of scalp dissecting cellulitis manifesting with furrows and gyri. J Eur Acad Dermatol Venereol. 2023 Feb 3.
LICHEN PLANOPILARIS Lim SH et al. Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235
GENERAL SCARRING ALOPECIA
Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2023 Nov 19:S
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA
Joshi TP et al. Comorbidities in patients with central centrifugal cicatricial alopecia: a case-control study. Int J Dermatol. 2023 Nov 23.
ACNE KELOIDALIS NUCHAE
Lobato-Berezo A et al. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1.
STUDIES REFERENCED IN THIS EPISODE
Pastukhova E et al. Alopecia Areata as a Sequela of COVID-19 Vaccination: A Systematic Review J Cutan Med Surg. 2023 Jan-Feb;27(1):64-65.
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Genco L et al. Alopecia Areata after COVID-19 Vaccines. Skin Appendage Disord. 2023 Mar;9(2):141-143.
STUDIES REVIEWED THIS WEEK:
Chang R et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023 Feb;56:101783
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023 Oct;42(10):2905-2914.
Lim SG et al. Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 JAMA Netw Open. 2023 Oct 2;6(10):e2336120.
Pastukhova E et al. Alopecia Areata as a Sequela of COVID-19 Vaccination: A Systematic Review J Cutan Med Surg. 2023 Jan-Feb;27(1):64-65.
STUDIES TO BE REVIEWED NEXT WEEK (PREVIEW)
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Genco L et al. Alopecia Areata after COVID-19 Vaccines. Skin Appendage Disord. 2023 Mar;9(2):141-143.
STUDIES REFERENCED IN THIS EPISODE:
Workman K and Kindred C (starts at 2:10). Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111.
Cook M et al (starts at 12:07). Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.
ARTICLES COVERED THIS WEEK
STUDY 1:
Ong M et al (starts at 5:12). Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6.
Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237
STUDY 2:
Imhof R et al (starts at 16:35). Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.
Ramos PM et al. Minoxidil 1 mg versus minoxidil 5 % topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol Jan 2020;82(1):252-253.
STUDY 3:
Jimenez-Cauhe J et al (starts at 24:27). Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
Vano-Galvan S et al. Safety of low dose oral minoxidil for hair loss: A multicenter study of 1404 patients. JAAD 2021; 84: 1644-51.
Sanabria B et al. Adverse effects of low dose oral minoxidil for
androgenetic alopecia in 435 patients. JAAD 2021; 84: 1175-78.
ARITCLES COVERED NEXT WEEK (PREVIEW)
Cook M et al. Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.
Workman K and Kindred C. Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111
ARTICLES REFERENCED IN THIS EPISODE
Krauss A (starts at 12:44). Why all randomised controlled trials produce biased results. Ann Med. 2018 Jun;50(4):312-322.
Van Noreen R (starts at 15:33). Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023 Jul;619(7970):454-458. Listen at https://youtu.be/_QLvzCr6nz4?feature=shared
Carlisle JB (starts at 16:28). False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021 Apr;76(4):472-479.
PREVIEW STUDIES FOR NEXT WEEK (SEASON 6, EPISODE 3)
Ong M et al. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6. doi: 10.1016/j.jaad.2023.10.010. Online ahead of print.
Jimenez-Cauhe et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
Imhof R et al. Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.
Studies Referenced in This Episode: Season 6 Episode 1
King B et al (starts at 4:07). When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023 Sep 14:ljad253.
Gargiulo L et al (starts at 30:22). Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat. 2023 Dec;34(1):2268764.
Preview of Studies for New Week: Season 6 Episode 2
Krauss A. Why all randomised controlled trials produce biased results. Ann Med. 2018 Jun;50(4):312-322.
Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021 Apr;76(4):472-479.
Van Noorden R. Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023 Jul;619(7970):454-458. Listen at https://youtu.be/_QLvzCr6nz4?feature=shared
On August 1, 2023, Dr Donovan announced the long awaited start of the Evidence Based Hair Fellowship training program. This is an online (virtual) training program for practitioners that wish to develop expertise in hair loss. The program runs Jan 2024 to August 2025 and participants meet once weekly for a three hour period (either on a Wednesday or a Thursday).
In this short recording, Dr Donovan updated listeners on the Evidence Based Hair Fellowship training program.
Interested participants may wish to watch video describing the full program at https://youtu.be/xWBT9sKWU_k?si=6TVCHw3lnNgb2_mk
or download the coarse syllabus at:
https://donovanmedical.com/donovan-hair-academy
Alopecia Areata Awareness Month - Recording from Sept 6 2023 Live Public Webinar hosted by Dr Donovan.
Question 1 (starts at 3:50): Is the rate of alopecia areata going up ?
Question 2 (starts at 7:45):What blood tests should be ordered for someone with alopecia areata?
Question 3 (starts at 11:58):Do JAK inhibitors cure alopecia areata?
Question 4 (starts at 15:45): What treatments are possible for eyelash loss?
Question 5 (starts at 17:53): What other medical problems do patients with alopecia areata have?
Question 6 (starts at 20:29): My son is 3 years old and Alopecia. 1 year ago, hair loss started and his hair and eyebrows completely fell out. In the tests , it was determined that his intestinal flora was very disordered and he has lactose and gluten intolerance. There are some doctors who have found that Intestinal Flora Disorder and Leaky Gut Syndrome can cause some autoimmune diseases. I would like to know your thoughts on this subject.
Question 7 (starts at 26:58): Should I ask for a biopsy to prove the diagnosis of alopecia areata?
Question 8 (starts at 29:01): I am a 37 year old female and have alopecia areata. Will I pass this on to my children?
Question 9 (starts at 31:48): Does stress cause alopecia areata? I hear mixed views.
Question 10 (starts at 35:16): My 3 year old developed a small area of alopecia over the summer. What treatment is considered best?
Question 11 (starts at 41:12): Does low vitamin D make alopecia worse?
Question 12 (starts at 43:43): My alopecia areata is becoming scarring. How is this possible?
Question 13 (starts at 47:13): Do you see loss of efficacy over time of JAK inhibitors and if so what would be the reason
STUDIES REFERENCE IN THE EPISODE
SWITCHING FROM TOFACITINIB TO BARICITINIB
Kazmi A et al (starts at 12:33). Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.
RITLECITINIB IN ADOLESCENTS
Hordinsky M et al (starts at 21:31). Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023 Jul 17.
RISK OF INFECTIONS, CANCER, HEART DISEASE AND BLOOD CLOTS IN AT/AU
George P et al (starts at 36:08). Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.
Schneeweiss MC et al (starts at 37:36). Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol. 2021 Jul 1;157(7):805-816.
MARKERS OF VENOUS THROMBOEMBOLISM IN ALOPECIA AREATA
Sudnik W et al (starts at 57:40) . The role of selectins in alopecia areata. Postepy Dermatol Alergol. 2015 Feb;32(1):27-32.
Shakoei S et al (starts at 58:23). Coagulation status in patients with alopecia areata: a cross-sectional study. Ital J Dermatol Venerol. 2021 Oct;156(5):588-592.
Waśkiel-Burnat A et al (starts at 59:30). Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about? Dermatol Ther (Heidelb). 2023 Aug;13(8):1847-1855.
HABIT REPLACEMENT THERAPY FOR TRICHOTILLOMANIA
Moritz S et al (starts at 1:04:34). Self-Help Habit Replacement in Individuals With Body-Focused Repetitive Behaviors: A Proof-of-Concept Randomized Clinical Trial. JAMA Dermatol. 2023 Jul 19;e232167.
LINK TO VIDEO on HRT DEMONSTRATION https://clinical-neuropsychology.de/habit-replacement-en/#sthash.J6iQiYRi.dpuf
NON SCARRING ALOPECIA AFTER HYALURONIC ACID TEMPORAL LIFTING TECHNIQUES
Landau M et al (starts at 9:05). Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37:30-34
Coimbra D.D., and de Oliveira B.S (starts at 10:17). Supra-auricular lifting with fillers: new technique. J Cosmet Dermatol. 2016;8(4):328–335.
CUTIS VERTICES GYRATA DUE TO PSORIASIS
Garcia-Rodriquez V et al (starts at 25:19). Cutis verticis gyrata secondary to scalp psoriasis. Int J Dermatol. 2023 Jun 4.
ORAL MINOXIDIL ASSOCIATED HYPERSENSITIVITY PNEUMONITIS
Takekosh D et al (starts at 32:35). Minoxidil-induced lung disease, masquerading as hypersensitivity pneumonitis. Respir Med Case Rep. 2023 Apr 29;43:101861.
PTSD AND AUTOIMMUNE DISEASE
Hsu TW et al (starts at 43:40). Risk of autoimmune diseases after post-traumatic stress disorder: A nationwide cohort study. Eur Arch Psychiatry Clin Neurosci. 2023 Jun 15.
Song H et al (starts at 49:18). Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018 Jun 19;319(23):2388-2400.
Dai Y-X et al (starts at 51:00). Posttraumatic Stress Disorder and the Associated Risk of Autoimmune Skin Diseases: A Nationwide Population-Based Cohort Study. Psychosom Med. 2021 Apr 1;83(3):212-217.
PATHERGY IN PATIENTS WITH BEHCET’S DISEASE RECEIVIGING LASER HAIR REMOVAL R
Nicolau et al (starts at 53:07). Pathergy-like reaction induced by laser hair removal in a patient with Behçet disease. Reumatismo. 2023 Jul 17;75(2).
Van der Ree-Pellikaan C et al (starts at 1:01:48). Oral ulcerations after placement of orthodontic braces and skin pustules after laser hair removal: novel inducers of pathergy reactions in new-onset Behçet's disease. BMJ Case Rep. 2016 Mar 7;2016:bcr2014209208. doi: 10.1136/bcr-2014-209208.
DISEASE ASSOCIATIONS IN FRONTAL FIBROSING ALOPECIA
Conic et al. Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.
Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
Lim SH Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235
THE RELATIONSHIP BETWEEN LPP AND HYPOTHYROIDISM
Joshi TP et al. Association of lichen planopilaris with hypothyroidism: a systematic review and meta-analysis. Int J Dermatol. 2023 Jul 10.
SIDE EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH SCARRING ALOPECIA
Ezemma O et al. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023 Apr 10. doi: 10.1111/ijd.16660. Online ahead of print
GENETICS OF MALE FRONTAL FIBROSING ALOPECIA
Rayinda T et al. Shared Genetic Risk Variants in Both Male and Female Frontal Fibrosing Alopecia. J Invest Dermatol. 2023 May 19;S0022-202X(23)02068-7.
INCIDENCE AND PREVALENCE OF FRONTAL FIBROSING ALOPECIA
Lavian J et al. Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. Dermatol Online J. 2021 Aug 15;27(8).
Trager MH et al. Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169
Carmona-Rodriquez M et al. Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases. Life (Basel). 2023 Jun 8;13(6):1344.
Season 4 Episode 4
COVID RELATED TE
Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.
M Alharbi et al. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022 Oct;11(10):6056-6060.
Tahmaz A et al. [The Evaluation of Long Coronavirus Disease Symptoms at Ninth Month from a Hospital in Türkiye]. .Mikrobiyol Bul. 2022 Oct;56(4):657-666.
Saber M et al. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023 Mar 9
Lv S et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection Clin Cosmet Investig Dermatol. 2021; 14: 385–387. Published online 2021 Apr 16.
Willimann B, et al. Hair pain (trichodynia): frequency and relationship to hair loss and patient gender. Dermatology. 2002
HAIR LOSS FROM ANTI-CGRP THERAPIES
Ruiz M et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023 Feb;43(2):3331024221143538.
Sessa M and Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35: 215–227
Evers S and Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023 Jan;63(1):165-167.
ORAL MINOXIDIL FOR TRACTION ALOPECIA
Awad A et al. Low-dose oral minoxidil improves hair density in traction alopecia. J Am Acad Dermatol. 2023 Feb 24;S0190-9622(23)00278-5.
Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.
Kim and Craiglow. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.
TINEA CAPITIS WORK UP AND TREATMENT IN PEDIATRICS
Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.
STUDIES REFERENCED
ROLE OF SCALP BIOPSIES IN BLACK WOMEN WITH HAIR LOSS
Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.
ORAL MINOXIDIL IN CHEMOTHERAPY RELATED HAIR LOSS
Kang J et al. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol 2022 Dec 13;S0190-9622(22)03261-3.
FOLLICULOTROPIC MYCOSIS FUNGOIDES
Paolino G et al. Widespread and eruptive comedonal lesions with alopecia. JAAD Case Rep . 2022 Nov 1;31:23-26.
Kreutzer and Effendy. Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides. Dermatol Ther (Heidelb). 2020 Oct;10(5):1175-1180
Gallo G et al Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports. 2021 May 18;11(1):10555.
ATRICHIA WITH PAPULES LESIONS
Boisen J et al. Atrichia With Papular Lesions Confirmed via Genetic Testing: A Case Report. Cureus 2022 Dec; 14(12): e32562.
Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol 2002; 118: 887–890
Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria. Acta Derm Venereol 2008; 88(4): 346–349.
Bergman R et al. The alopecias associated with vitamin D-dependent rickets type IIA and with hairless gene mutations: a comparative clinical, histologic, and immunohistochemical study. Arch Dermatol. 2005 Mar;141(3):343-51.
METHOTREXATE AND LIVER FIBROSIS
Atallah E et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol . 2023 Jan 23;S0168-8278(23)00020-X.
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015;45(2):156–162
Cheema HI et al. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022 Oct;70(7):1452-1460.
STUDIES REFERENCED PATHOLOGY OF NON SCARRING AND SCARRING ALOPECIA Amanda Araujo Dos Reis Botega et al. Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study Skin Appendage Disord. 2023 Jan;9(1):34-41. doi: 10.1159/000526966. Epub 2022 Nov 25. HYDROXYCHLOROQUINE AND RETINOPATHY RISK Ronald B Melles RB et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 Jan 17. LOW DOSE NALTREXONE IN LICHEN PLANOPILARIS Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020 Hamel RK et al. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus Jan 2023. Toledo-Pastrana et al. Perifollicular Erythema as a Trichoscopy Sign of Progression in Frontal Fibrosing Alopecia. Int J Trichology. 2013 Jul-Sep; 5(3): 151–153. ACTINIC LICHEN PLANOPILARISLalagianni N et al. Actinic lichen planopilaris: a new variant of lichen planopilaris triggered by ultraviolet radiation. Clin Exp Dermatol. 2023 Feb 2;48(2):158-160. FOLLICULITIS DECALVANS MICROBIOME STUDIES Moreno-Arrones OM et al. Folliculitis decalvans has a heterogeneous microbiological signature and impaired immunological response. Dermatology. 2023 Jan 30. Moreno-Arrones et al. Folliculitis decalvans microbiologic signature is specific for disease clinical phenotype. J Am Acad Dermatol. 2021 Nov;85(5):1355-1357. TNF INHIBITORS IN DISSECTING CELLULITISAlzahrani M et al. Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter STUDY. Clin Exp Dermatol. 2023 Jan 26;llad036.
The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in hair shedding, scarring alopecia, seborrheic dermatitis and hair straighteners (studies 12 to 20). Studies 1 to 11 are found in Part 1 (season 3 episode 9)
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
STUDIES IN SCARRING ALOPECIA
STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
STUDIES IN VARIOUS TOPICS
STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
STUDIES IN PART 1 of PODCAST
STUDIES IN AGA
STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
STUDY 9: Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
STUDIES IN ALOPECIA AREATA
STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in androgenetic alopecia and alopecia areata (studies 1 to 11). Studies 12 to 20 are found in Part 2 (season 3 episode 10)
STUDIES IN FEMALE PATTERN HAIR LOSS AND MALE PATTERN HAIR LOSS
STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
STUDY 9: Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
STUDIES IN ALOPECIA AREATA
STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
STUDIES IN SCARRING ALOPECIA
STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
STUDIES IN VARIOUS TOPICS
STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
STUDIES REFERENCED
ROLE OF CORTICOSTEROIDS IN THE JAK INHIBITOR ERA
Licata G et al (starts at 7:21). Management of alopecia areata in JAK-inhibitors era: are systemic and topical corticosteroids still useful? Int J Dermatol. 2022 Nov 13.
ALOPECIA AREATA AND PERIODONTITIS
Kim JS et al (starts at 17:15). Periodontitis and risk of alopecia areata: A nationwide population-based cohort study in Korea. J Eur Acad Dermatol Venereol. 2022 Nov 17.
ALOPECIA AREATA AND MICRONEEDLING
Arora A et al (starts at 23:33). Comparative Efficacy of Injection Triamcinolone Acetonide given Intralesionally and through Microneedling in Alopecia areata. Int J Trichology. 2022 Sep-Oct;14(5):156-161.
Chandrashekar BS et al (starts at 27:42). Alopecia areata-successful outcome with microneedling and triamcinolone acetonide. J Cutan Aesthet Surg. 2014 Jan;7(1):63-4.
HAIR LOSS IN TRANSGENDER INDIVIDUALS
C Cocchetti et al (starts at 32:04). Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI). J Endocrinol Invest. 2022 Nov 8.
MICRONEEDLING TO TREAT ANDROGENETIC ALOPECIA
Lingling Jia et al (starts at 38:21). Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia. J Cosmet Dermatol. 2022 Jul 21.
Dhurat R et al (starts at 40:18). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013 Jan;5(1):6-11.
Liang X et al (starts at 43:49). Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
A mix of recently published studies in hair loss
IRON PILL GASTRITIS
Koch R et al (starts at5 5:19). Case report: Rapid onset, ischemic-type gastritis after initiating oral iron supplementation. Front Med (Lausanne) 2022 Nov 3;9:1010897.
Laine LA et al. (starts at 9:17). Effect of oral iron therapy on the upper gastrointestinal tract. A prospective evaluation. Dig Dis Sci. (1988) 33:172–7. doi: 10.1007/BF01535729
COMPARISON OF HORIZONTAL VS VERTICAL SECTIONING FOR SCALP BIOPSIES
Yadav et al (starts at 14:05). Vertical versus transverse sectioning in histopathological diagnosis of alopecia: A comparative study. Indian J Dermatol Venereol Leprol. 2022 Sep 17;1-4.
Du et al (starts at 22:40). Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis. Eur J Dermatol . 2016 Aug 1;26(4):361-9. doi: 10.1684/ejd.2016.2797.
Nguyen J et al (starts at 27:13). The HoVert technique: A novel method for the sectioning of alopecia biopsies. J Cutan Pathol. 2011;38:401–6.
PERSISTENT HIVES AFTER LASER HAIR REMOVAL
Dorgham N et al (starts at 27:36). Severe persistent urticaria following laser hair reduction. J Cosmet Dermatol. 2022 Sep 15.
Landa N et al (starts at . Urticaria induced by laser epilation: a clinical and histopathological study with extended follow-up in 36 patients. Lasers Surg Med. 2012;44(5):384-389.
HAIR REPIGMENTATION FROM NILOTINIB
Kockerols CCB, Westerweel PE (starts at 34:24). Hair Repigmentation Induced by Nilotinib. N Engl J Med. 2022 Aug 11;387(6):e12. doi: 10.1056/NEJMicm2119953. Epub 2022 Aug 6.
SEBORRHEIC DERMATITIS AND OSTEOPOROSIS
Ying-Yi Lu et al (starts at 37:01) . Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
SEBORRHEIC DERMATITIS AND PARKINSON’S DISEASE
Tomic S et al (starts at 47:09). Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson's Disease. J Clin Neurol. 2022 Nov;18(6):628-634.
FINASTERIDE AND BLADDER CANCER.
Garg H et al (starts at 53:52). Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis. Clin Genitourin Cancer. 2022 Oct 29;S1558-7673(22)00221-X
LEARNING OBJECTIVES
By the end of the podcast, the listener should be able to
- Discuss the benefits of HCQ in LPP
- Outline allergens that may be relevant in LPP/FFA
- Discuss the benefits of LDOM in LPP
- Describe the Renbok phenomenon and how it relates to FFA
- Outline the potential triggers for EPDS
- Describe the relationship between AKN and gout
EFFICACY OF HYDROXYCHLOROQUINE IN LICHEN PLANOPILARIS
Vastarella M et al (starts at 6:08). Efficacy and safety of hydroxychloroquine for the management of lichen planopilaris in a real-life setting. Ital J Dermatol Venerol. 2022 Jun;157(3):296-297.
Chiang C et al (starts at 14:17). Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010 Mar;62(3):387-92.
Dhonncha EN et al (starts at 16:05). The role of hydroxychloroquine in the treatment of lichen planopilaris: A retrospective case series and review. Dermatol Ther. 2017 May;30(3).
ALLERGIC CONTACT DERMATITIS IN LICHEN PLANOPILARIS AND FRONTAL FIBROSING ALOPECIA
Prasad et al (starts at 18:38). Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: A cohort study J Am Acad Dermatol Aug 2020
Shtaynberger B et al (starts at 22:51). The Prevalence of Type IV Hypersensitivity in Patients With Lichen Planopilaris and Frontal Fibrosing Alopecia. Dermatitis. 2022 Oct 17.
USE OF ORAL MINOXIDIL IN LICHEN PLANOPILARIS
Vano-Galvan S et al (starts at 36:42). Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol 2021 Jun;84(6):1684-1686.
Giuseppe Gallo et al (starts at 37:45). Low-dose oral minoxidil in female patients with lichen planopilaris: Real-life experience. J Eur Acad Dermatol Venereol. 2022 Aug 16
RENBOK PHENOMENON IN FRONTAL FIBROSING ALOPECIA
Sławińska M et al (starts at 42:29). Frontal fibrosing alopecia sparing a dermal melanocytic nevus: a report of two cases of Renbök phenomenon. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):e1042-e1043.
EROSIVE PUSTULAR DERMATOSIS AND SHINGLES
Salah NB et al (starts at 45:21). Erosive pustular dermatosis of the scalp in the COVID-19 era. J Cosmet Dermatol. 2022 Nov 14.
Akpandak I et al (starts at 50:55). Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine. JAMA Netw Open 2022 Nov 1;5(11):e2242240.
RISK OF GOUT IN ACNE KELOIDALIS
Eran Shavit et al (starts at 53:40). The burden of gout in acne keloidalis nuchae-Insights from a population-based study. J Cosmet Dermatol. 2022 Nov 8.
Studies in Androgenetic Alopecia and Alopecia Areata
STUDIES REFERENCED
MINOXIDIL CONCENTRATIONS
Singh et al (starts at 10:10). Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? Clin Exp Dermatol. 2022 Nov;47(11):1951-1955
Olsen EA, Dunlap FE, Funicella T et al (starts at 13:22). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377–85
McCoy J, Goren A, Kovacevic M, Shapiro J (starts at 16:02). Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 2016;30: 1153–5
Goldust M (starts at 17:25). Minoxidil 15% solution versus minoxidil 5%solution in the treatment of androgenetic alopecia. Br JDermatol 2020;183(Suppl): 91 (abstract BH107)
Ghonemy S, Alarawi A, Bessar H (starts at 18:11). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgeneticalopecia: a trichoscopic evaluation. J Dermatolog Treat 2021;32: 236–41
JAK INHBITORS FOR ANDROGENETIC ALOPECIA
Casale F et al (starts at 22:19). Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia? Int J Dermatol. 2022 Nov;61(11):e457-e458.
BOTOX FOR ANDROGENETIC ALOPECIA
English RS Jr and Ruiz S (starts at 29:30). Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review. Skin Appendage Disord. 2022 Mar;8(2):93-100
Shon U, Kim MH, Lee DY, Kim SH, Park BC (starts at 33:48). The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020 Dec;83(6):1838–9.
PLATELET RICH PLASMA TREATMENTS FOR ANDROGENETIC ALOPECIA
Gupta AK and Bamimore M (starts at 39:09). Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
de Oliveira AFQ et al (starts at 42:25). Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. J Dermatolog Treat. 2022 Oct 31:1-11.
LOW DOSE ORAL MINOXIDIL SIDE EFFECTS
Dlova et al (starts 45:41). Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022 Aug 11;28:94-96.
Randolph M, Tosti A (starts at 53:22). Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3): 737-746.
LOW DOSE ORAL MINOXIDIL EFFICACY AND SAFETY
Gupta AK et al (starts at 57:33). There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
JAK INHIBITORS AND VENOUS THROMBOEMBOLISM
Chen T-L et al (starts at 1:02:14). Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Aug 24;e223516.
King B et al (1:05:33). Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
Misra D et al (starts at 1:11:19). Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box. Clin Rheumatol. 2022 Oct 20.
RISING PREVALENCE OF ALOPECIA AREATA IN JAPAN
Campos-Alberto E et al (starts at 1:13:00). Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database. J Dermatol. 2022 Nov 2.
COVID VACCINATION AND ALOPECIA AREATA RISK
Tassone F et al (starts at 1:15:21). Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study. Vaccines (Basel). 2022 Sep 5;10(9):1467.
Nguyen B and Tosti A (starts at 1:21:22). Alopecia areata after COVID-19. J Eur Acad Dermatol Venereol. 2022 Aug 11;10.1111/jdv.18491.
Babadjouni A et al (starts at 1:30:21). COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy. JAAD Case Rep . 2022 Nov;29:181-185.
Chen C-H et al (starts at 1:36:55). Intractable alopecia areata following the second dose of COVID-19 vaccination: Report of two cases. Dermatol Ther. 2022 Sep;35(9):e15689.
Recording of the Evidence Based Hair Podcast for the Oct 24, 2022 issue.
STUDIES REFERENCED
Han JJ et al (starts at 5:28) Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study. J Am Acad Dermatol. 2022 Jul;87(1):151-153.
Gressler J et al (starts at 20:55 ). Re-pigmentation of scalp hair - A feature of early melanoma. Am J Med. 2022 Sep 25;S0002-9343(22)00711-2.
Lackey A et al (starts at 24:09) Repigmentation of gray hairs with lentigo maligna and response to topical imiquimod. JAAD Case Rep. 2019 Dec; 5(12): 1015–1017
Nguyen et al (starts at 27:18). Characterizing and assessing the reliability of TikTok's most viewed alopecia-related videos. J Eur Acad Dermatol Venereol. 2022 Aug 14.
Nagrani NS, Goldberg LJ (starts at 37:24). Sebaceous gland atrophy in seborrheic dermatitis of the scalp; a pilot study. J Cutan Pathol. 2022 Nov;49(11):988-992.
Headington JT, Gupta AK, Goldfarb MT, et al (starts at 41:26). A morphometric and histologic study of the scalp in psoriasis. Paradoxical sebaceous gland atrophy and decreased hair shaft diameters without alopecia. Arch Dermatol. 1989;125:639-642.
Klein EJ et al (starts at 46:38). Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. JAAD Int. 2022 Aug 30;9:69-71.
Chang CJ et al (starts at 59:21). Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
Recording of the Evidence Based Hair Podcast for the Oct 17, 2022 issue.
LICHEN PLANOPILARIS COMORBIDITY STUDIES
Conic et al (starts 8:19). Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.
Joshi et al (starts 9:59). Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
Nasimi et al (starts 15:45) Comorbidities in Patients with Lichen Planopilaris: A Case-Control Study. Skin Appendage Disord. 2022 Jul;8(4):302-306.
FRONTAL FIBROSING ALOPECIA STUDIES
Imhof RL et al (starts 20:21). Eyebrow hair loss as a prognostic factor for frontal fibrosing alopecia. JAAD Int. 2022 Aug 18;
Rosales Santillan M et al (starts 26:52). Exploring potential decreasing age of patients with frontal fibrosing alopecia. JAAD Int. 2022 Jul 22;
Doche et al (starts 35:52). "Normal-appearing" scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients. Exp Dermatol . 2020 Mar;29(3):278-281.
Porrino-Bustamante et al (starts 36:30). Frontal Fibrosing Alopecia: A Histopathological Comparison of the Frontal Hairline with Normal-Appearing Scalp. J Clin Med 2022; Jul 15;11(14):4121
CHECKPOINT INHIBITORS AND SCARRING ALOPECIA
Braasch et al (starts 45:25). Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases. Acta Derm Venereol. 2022 Oct 11;102:adv00792.
GENE SIGNATURES IN PRIMARY SCARRING ALOPECIA
Wang EHC et al (starts 55:10). Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways. PNAS Nexus . 2022 Jul 11;1(3):pgac111
ALOPECIC AND ASEPTIC NODULES OF THE SCALP (AANS):
Luu NHC et al (starts 1:06:42). Alopecic and Aseptic Nodules of the Scalp: A New Entity or a Minor Form of Dissecting Cellulitis? Int J Trichology. 2022 Jul-Aug;14(4):120-124
Recording of the Evidence Based Hair Podcast for the Oct 11, 2022 issue.
TINEA CAPITIS STUDIES
Cukierman E et al (starts at 5:18). Alopecia and pet: a case report. Einstein (Sao Paulo). 2022 Jul 4;20:eRC6881.
TELOGEN EFFLUVIUM - COVID 19
Visconti A et al (starts at 20:00) Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App. Br J Dermatol. 2022 Jul 22;
TELOGEN EFFLUVIUM - ISOTRETINOIN
Tran PT et al (starts at 29:30) Characteristics of Patients with Hair Loss after Isotretinoin Treatment: A Retrospective Review Study. Int J Trichology. 2022 Jul-Aug;14(4):125-127.
TRICHOTILLOMANIA STUDIES
Grant JE and Chamberlain SR (starts at 42:17). Natural recovery in trichotillomania. Aust N Z J Psychiatry. 2022 Oct;56(10):1357-1362
Chesivoir EK et al (starts at 47:30). Comorbid trichotillomania and attention deficit hyperactivity disorder in adults. Psychiatry. 2022 Jul; TELOGEN EFFLUVIUM -
IRON DEFICIENCY
Kano Y. Blue sclera (starts at 55:33): An overlooked finding of iron deficiency. Cleve Clin J Med. 2022 Oct 3;89(10):549-550.
ORAL MINOXIDIL IN PEDIATRICS
Jerjen R et al. Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184(5):977-978.
Nicolas-Ruanes et al. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol. 2022 Apr 26;
John JM et al. Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review. J Am Acad Dermatol . 2022 Jul 5;S0190-9622(22)02245-9.
HAIR FIBERS AND CAMOUFLAGE
Ring and Keller. Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients. J Am Acad Dermatol. 2017 Jun;76(6):1186-1189
Babadjouni A et al. Patient Satisfaction and Adverse Effects Following the use of Topical Hair Fiber Fillers. Int J Trichology. 2022 May-Jun; 14(3): 97–102
HYDROXYCHLOROQUINE IN PREGNANCY
Reynolds JA et al. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford). 2022 Jun 29:
Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9.
Kaplan Y et al. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 May;81(5):835-48.
Clowse MEB et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022 Mar;9(1):e000651.
Huybrechts K et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021 Mar;224(3):290.e1-290.e22
Huybrechts K et al. Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence. Am J Obstet Gynecol. 2021 May;224(5):549-550.
Bérard et al. Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Front Pharmacol. 2021 Aug 2;12:722511.
Howley et al. Maternal exposure to hydroxychloroquine and birth defects. Birth Defects Res. 2021 Oct 15;113(17):1245-1256.
Andersson et al. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021 May 14;60(5):2317-2326.
TERIFLUNOMIDE INDUCED HAIR LOSS IN MULTIPLE SCLEROSIS
Travis LH et al. Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice? Neurol Ther. 2018 Dec; 7(2): 341–347.
Porwal MH et al. Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies. J Cent Nerv Syst Dis. 2022 Jun 23;14:11795735221109674.
DO IT YOURSELF LOW-ALLERGEN PRODUCTS
Xiong M and Warshaw EM Hair Care Product Hacks: Do It Yourself Alternatives. Dermatitis. 2022 Jun 29.
Zirwas M and Moennich J. Shampoos. Dermatitis. 2009 Mar-Apr;20(2):106-10
Tawfik M, Rodriguez-Homs LG, Alexander T, et al. Allergen content of best-selling ethnic versus nonethnic shampoos, conditioners, and styling products. Dermatitis 2021;32(2):101–110
https://donovanmedical.com/diy
PREMATURE GREYING (EARLY CANITIES)
Anggraini et al. Risk Factors Associated with Premature Hair Greying of Young Adult. Open Access Maced J Med Sci . 2019 Nov 14;7(22):3762-3764.
Dawber RP. Integumentary associations of pernicious anaemia. Br J Dermatol . 1970 Mar;82(3):221-3.
Mosley JG and Gibbs AC. Premature grey hair and hair loss among smokers: a new opportunity for health education? British Medical Journal 1996; 313: 1616.
Bhat RM et al. Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. Int J Trichology. 2013;5:17–21.
Chang H-C and Sung C-W. Association between serum levels of minerals and premature hair graying: a systematic review and meta-analysis. Int J Dermatol. 2020 Oct;59(10):e378-e380.
Schnohr P et al. Longevity and gray hair, baldness, facial wrinkles, and arcus senilis in 13,000 men and women: The Copenhagen city heart study. J Gerontol A Biol Sci Med Sci. 1998;53:M347–50.
Schnohr P et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J 1995 Nov;130(5):1003-10.Vinay K, Yadav S, Handa S. Zinc deficiency and canities: An unusual manifestation. JAMA Dermatol. 2014;150:1116–7
Kocaman SA, Cetin M, Durakoðlugil ME, Erdoðan T, Canga A, Ciçek Y, et al . The degree of premature hair graying as an independent risk marker for coronary artery disease: A predictor of biological age rather than chronological age. Anadolu Kardiyol Derg 2012;12:457-63.
Paik S et al Association Between Premature Hair Greying and Metabolic Risk Factors: A Cross-sectional Study. Acta Derm Venereo. 2018 Aug 29;98(8):748-752.
Mahendiratta S et al. Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal-A systematic review and meta-analysis. Dermatol Ther. 2020 Nov;33(6):e13990.
Das S et al. Cardiovascular risk markers in premature canities. Indian J Dermatol Venereol Leprol. 2022 Jun 30;1-5.
FRONTAL FIBROSING ALOPECIA :
ISOTRETINOIN VS FINASTERIDE
Rakowska A, et al (starts at 9:15). Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases. J Drugs Dermatol. 2017.
Rokni GR et al (starts at 10:43). Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia - A randomized controlled trial. J Cosmet Dermatol. 2022 Jul 11.
FRONTAL FIBROSING ALOPECIA : EYELASH INVOLVEMENT
Salas-Callo C et al (starts at 16:14). Eyelash involvement in frontal fibrosing alopecia: A prospective study. J Am Acad Dermatol 2022 Jul;87(1):232-234.
FRONTAL FIBROSING ALOPECIA : QUALITY OF LIFE
David Saceda-Corralo et al (starts at 22:52). Health-Related Quality of Life in Patients With Frontal Fibrosing Alopecia. JAMA Dermatol. 2018 Apr 1;154(4):479-480.
Varghae A et al (starts at 24:43). Assessment of health-related quality of life in patients with frontal fibrosing alopecia. J Cosmet Dermatol. 2022 Jun 27.
FRONTAL FIBROSING ALOPECIA : MALE FFA STUDIES OF ORAL MINOXIDIL AND FINASTERIDE/DUTASTERIDE
Moussa A et al (starts at 30:00). Clinical features and treatment outcomes of frontal fibrosing alopecia in men. Int J Dermatol. 2022 Jun 21
LPP PREVALENCE STUDIES
Trager MH et al (starts at 40:50). Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169
Lavian J et al (starts at 41:37). Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system.Dermatol Online J. 2021 Aug 15;27(8).
Lim S H et al (starts at 42:29). Rapidly increasing incidence and prevalence of lichen planopilaris in an Asian population: A Korean nationwide population-based study. J Dermatol. 2022 Jun 21.
Joshi TP et al (starts at 49:10). Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA: QUALITY OF LIFE
Akintilo et al (starts at 54:48). Health care barriers and quality of life in central centrifugal cicatricial alopecia patients. Cutis. 2018 Dec;102(6):427-432.
Maranga et al (starts at 56:49). Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study. Br J Dermatol. 2022 Jun 15.
CONCLUSION AND SUMMARY - starts at 58:46
STUDIES REFERENCED
COVID RELATED SHEDDING
Mazeto IFS et al (starts at 6:09). Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
Czech T et al (starts at 14:30). Characteristics of Hair Loss after COVID-19: Systematic Scoping Review. J Cosmet Dermatol. 2022 Jul 8.
TRICTHOTILLOMANIA
Thomson H et al (starts at 24:58). Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. J Psychiatr Res. 2022 Jul 1;153:73-81.
TINEA CAPITIS
Lecerf P et al (starts at 30:10). Asymptomatic Scalp Carriage among Household Contacts of Children Affected by Tinea Capitis: A Prospective Study in the Metropolitan Area of Brussels, Belgium. Skin Appendage Disord. 2022 May;8(3):200-205.
TRACTION ALOPECIA
Lucia GS et al (starts at 42:30). Traction alopecia: Neglected in women and children of color. J Am Acad Dermatol. 2022 May 28;
FINAL COMMENTS AND SUMMARY - starts at 49:03
Kavadya T and Mysore V (starts at 5:24). Role of Smoking in Androgenetic Alopecia: A Systematic Review. Int J Trichology. 2022 Mar-Apr; 14(2): 41–48.
Mosley JG and Gibbs AC (starts at 6;30). Premature grey hair and hair loss among smokers: a new opportunity for heatlh education? British Medical Journal 1996; 313: 1616.
Su LH and Chen T H-H (starts at 7:38) Association of Androgenetic Alopecia with Smoking and Its Prevalence Among Asian Men. Archives of Dermatology 2007 143; 1401-1406.
Calvao J et al (starts at 9:16). Finasteride and Floppy Iris Syndrome: What Role Can the Dermatologist Play? Int J Trichology. May-Jun 2022;14(3):115-116.
Ting H-C et al (starts at 14:04). Association between alopecia areata and retinal diseases: A nationwide population-based cohort study. J Am Acad Dermatol . 2021 Nov 1;S0190-9622(21)02735-3.
Thatiparthi A et al (starts at 15:56). Inflammatory ocular comorbidities in alopecia areata: a retrospective cohort study of a single academic center. J Am Acad Dermatol. 2022 Jun 16;S0190-9622(22)01009-X
Albela H et al (starts at 19:32). Efficacy and Tolerability of Methotrexate in the Treatment of Severe Paediatric Alopecia Areata. Skin Appendage Disord. 2022 May;8(3):206-210.
Barton V et al (starts at 24:20). Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2022 Jun;86(6):1318-1334.
Gambardella A, et al (starts at 29:18). Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata. Dermatitis 2021; 32: e85–e86.
Cantelli M et al (starts at 31:35). Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022; 1: e15346
Asfour et al (starts at 32:35). Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib. Int J Dermatol. 2022 Jun 20.
Gori N et al (starts at 33:53). Assessment of alopecia areata universalis successfully treated with upadacitinib. Int J Dermatol. 2022 Jul 2.
Conclusions and Summary (starts at 37:24)
JAK KINASE INHIBITORS AND SKIN CANCER
Jalles et al (starts at 5:29). Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis. Therapie. 2022 May 7;S0040-5957(22)00092-0.
ISOTRETINOIN LAB MONITORING
Xia E et al (starts at 13:36). Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study. JAMA Dermatol. 2022 Jun 15.
ISOTRETINOIN & SURGERY
Davis and Perkins (starts at 18:28). Oral isotretinoin (Roaccutane) use during incisional surgery: safe or risky? Case Reports Plast Surg Hand Surg. 2022 May 13;9(1):131-134.
Spring L et al (starts at 20:17). Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol. 2017 Aug 1;153(8):802-809.
Mysore V et al. Standard Guidelines of Care: Performing Procedures in Patients on or Recently Administered with Isotretinoin J Cutan Aesthet Surg. 2017 Oct-Dec; 10(4): 186–194.
CONGENITAL TRIANGULAR ALOPECIA
Shimrada K et al (starts at 23:57). Atypical Localization of Congenital Triangular Alopecia Associated with Down's Syndrome. Indian J Dermatol. 2022 Jan-Feb; 67(1): 94
Starace M et al (starts at 25:40). Atypical Presentation of Congenital Triangular Alopecia: A Case Series in Italy. Dermatol Pract Concept Oct 2020.
HYDROXYCHLOROQUINE DOSING
Chen R et al (ssarts at 30:00). Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices Ophthalmic Surg Lasers Imaging Retina. 2022 Jun;53(6):310-316.
Melles & Marmor (starts at 31:24). The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy. JAMA Ophthalmol. 2014;132(12):1453–1460.
The third Monday of the month is dedicated to studies in scarring alopecia.
LICHEN PLANOPILARIS
Kahjoogh et al (starts at 5:34). Efficacy, safety, tolerability and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: a triple arm blinded randomized controlled trial. Dermatol Ther. 2022 Jun 15
HYDROXYCHLOROQUINE
Beatriz Samões et al (starts at 24:05). Hydroxychloroquine induced melanosis. Reumatol Clin (Engl Ed). Jun-Jul 2022;18(6):377-378.
LINEAR SCLERODERMA
de Marsillac P et al (starts at 27:53). Clinical, epidemiological, trichoscopic and histopathological features of linear morphea on the scalp. J Eur Acad Dermatol Venereol. 2022 Jun 13. doi: 10.1111/jdv.18323. Online ahead of print
Ulc E et al (starts at 40:40). Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review. J Clin Med.
DISSECTING CELLULITIS
Melo DF et al (starts at 42:41). Dissecting cellulitis in women: a retrospective multicenter study with 17 patients. Int J Dermatol. 2022 May 15. doi: 10.1111/ijd.16271. Online ahead of print. May;86(5):e207-e208.
Ward N et al (starts at 48:03). Dissecting cellulitis of the scalp associated with peripheral and axial spondyloarthritis: report of a case and review of the literature. Clin Rheumatol 2022 Apr 23.
DYSTROPHIC ANAGEN EFFLUVIUM IN COVID 19 SHEDDING
Shanshal M (start 7:52). COVID-19 related anagen effluvium. J Dermatolog Treat. 2022 Mar;33(2):1114-1115.
Anna Carolina Miola et al (starts 9:45). Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
ALTERNATE DAY IRON DOSING
Lale Aydın Kaynar et al (starts 12:57). Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia. Ann Hematol. 2022 Apr 23.
Stoffel NU et al (starts 17:23). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-e533.
Mehta S et al (starts 19:03). A Prospective, Randomized, Interventional Study of Oral Iron Supplementation Comparing Daily Dose with Alternate Day Regimen Using Hepcidin as a Biomarker in Iron Deficiency Anemia. J Assoc Physicians India. 2020 May;68(5):39-41.
INTRAVENOUS IRON
Aratsu et al (starts 22:57). Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions. JAMA Netw Open. 2022 Mar; 5(3): e224488.
SSRI AND HAIR LOSS
Etiman M et al (starts 29:44). Risk of hair loss with different antidepressants: a comparative retrospective cohort study. Int Clin Psychopharmacol 2018 Jan;33(1):44-48.
Pejcic and Paudel (starts 31:17). Alopecia associated with the use of selective serotonin reuptake inhibitors: Systematic review. Psychiatry Res. 2022 May 10;313:114620. ;86(5):e207-e208.
TRACTION ALOPECIA
Beach RA (starts 35:56). Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.
Kim and Craiglow (starts 36:38). Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.
N ACETYL CYSTEINE IN TRICHOTILLOMANIA
Grant JE et al (starts 44:20). Arch Gen Psychiatry 2009
Bloch MH et al (starts 46:05) N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):231-40.
Popova L and Mancuso J (starts 48:09). Dramatic Improvement of Trichotillomania with 6 Months of Treatment With N-Acetylcysteine. Glob Pediatr Health. 2022 Mar 14;9:2333794X221086576.
ANDROGENETIC ALOPECIA STUDIES
Sanabria et al (starts at 4:40). Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
Klein E et al (starts at 13:40). Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
Cao L et al (starts at 21:19). Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
Emmanuel Sánchez-Meza et al (starts at 28:17). Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2022 Jun 1. doi: 10.1111/jdv.18285.
David Saceda-Corralo et al. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology. 2017 Jul-Sep; 9(3): 143–145.
Liamsombut S et al (starts at 34:45). Sleep quality in men with androgenetic alopecia. Sleep and Breathing. 2022 Apr 25.
ALOPECIA AREATA STUDIES
Anna Waśkiel-Burnat et al (starts at 41:33). Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
Conic et al. Prevalence of cardiac and metabolic diseases among patients with alopecia areata.J Eur Acad Dermatol Venereol . 2021 Feb;35(2):e128-e129.
Youssef S et al (starts at 48:28). Tofacitinib Therapy for Alopecia Areata is not Associated with Adverse Events during COVID-19 Infection. J Am Acad Dermatol. 2022 May 9;S0190-9622(22)00795-2.
McKenzie P et al (starts at 53:32). Evaluation of the Prevalence and Incidence of Pediatric Alopecia Areata Using Electronic Health Record Data. JAMA Dermatol. 2022 May 1;158(5):547-551.
Recording of the Evidence Based Hair Podcast for the May 23, 2022 issue.
ORAL MINOXIDIL USE IN PEDIATRIC PATIENTS
Nicolas-Ruanes et al (starts at 4:00). Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol. 2022 Apr 26;
Jerjen R et al. Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184(5):977-978.
ORAL MINOXIDIL COMPOUNDING ERRORS
Moreno-Arrones OM et al (starts at 9:06). Serious Adverse effects From Compounding Errors With Low-Dose Oral Minoxidil for Alopecia Treatment. Actas Dermosifiliogr. 2022 May 12;S0001-7310(22)00414-8.
DOXYCYCLINE SKIN PIGMENTATION
Afrin et al (starts at 17:15). Doxycycline-Associated Hyperpigmentation: A Case Report and Literature Review. Cureus. 2022 Apr 2;14(4):e23754.
SCALP SARCOIDOSIS
Kim JC and Lee ES (starts at 22:06). Unusual Case of Scalp Sarcoidosis with Alopecia: An Only Manifestation of Cutaneous Sarcoidosis without Systemic Involvement. Ann Dermatol. 2022 Apr;34(2):154-156.
Long T et al. Severe scalp sarcoidosis in an unlikely patient. JAAD Case Rep. 2020 Apr 24;6(11):1165-1166.
House NS et al. Sarcoidosis-induced alopecia.Dermatol Online J 2012 Aug 15;18(8):4.
Ghosh A et al. Single lesion of sarcoidosis presenting as cicatricial alopecia: a rare report from India. Int J Trichology . 2014 Apr;6(2):63-6.
Prohaska J et al. Scalp Sarcoidosis Presenting as Cicatricial Alopecia. J Am Osteopath Assoc. 2018 Dec 1;118(12):824-826.
Conde K et al. Lupus Pernio in Chronic Sarcoidosis. Cureus 2021 Sep; 13(9): e18331.
Hubail et al. Lupus pernio (Besnier-Tenneson syndrome): A rare form of sarcoidosis. Dermatol Reports 2018 Oct 1; 10(2): 7696.
Gopikrishnan Anjaneyan and Rita Vora Lupus pernio without systemic involvement. Indian Dermatol Online J. 2013 Oct-Dec; 4(4): 314–317.
JAK INHIBITOR SAFETY
Hoisnard L et al (starts at 37:53). Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022 May 3;12(1):7140
EYELASH TRICHOMEGALY WITH EGFR INHIBITORS
Inamadar S and Kumar NSP (starts at 59:03). Lady with Long Eyelashes… Int J Trichology. Mar-Apr 2022;14(2):71-72.
Evidence Based Hair Podcast for the May 16, 2022 issue.
STUDIES REFERENCED FRONTAL FIBROSING ALOPECIA STUDIES Arasu et al (starts at 3:40). Vitamin D status in patients with frontal fibrosing alopecia: A retrospective study. JAAD Int. 2022 Apr 18;7:129-130. Sun et al (starts at 11:30). Extensive facial scarring after ablative laser resurfacing in a patient with frontal fibrosing alopecia. JAAD Case Rep. 2022 Mar 26;23:123-127 Lobato-Berezo et al (starts at 18:32). Pustular frontal fibrosing alopecia: a new variant within the folliculitis decalvans and lichen planopilaris phenotypic spectrum? Br J Dermatol. 2022 May;186(5):905-907. Rocha VB et al (starts at 22:50). Uncommon subtypes of frontal fibrosing alopecia: retrospective analysis of clinical characteristics and prognosis. Anais Brasileiros de Dermatologia An Bras Dermatol. Mar-Apr 2022;97(2):260-262. LICHEN PLANOPILARIS STUDIES Diab R et al (starts at 30:17). Lichen planus and lichen planopilaris flare after COVID-19 vaccination. Dermatol Ther. 2022 Mar;35(3):e15283. DISSECTING CELLULITIS STUDIES Babalola et al (starts at 35:27). Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab. J Drugs Dermatol. 2022 Mar 1;21(3):313-314. Awad A and Sinclair R (starts at 42:45). Treatment of dissecting cellulitis of the scalp with Tildrakizumab. Australas J Dermatol 2022 May 4
Recording of the Evidence Based Hair Podcast for the April 25, 2022 issue.
STUDIES REFERENCED
ALLERGIC CONTACT DERMATITIS STUDIES
Feryel A et al (starts at 3:51). Unusual clinical presentation of allergic contact dermatitis to topical minoxidil. Contact Dermatitis. 2022 Mar 28
Pham et al (starts at 12:18). Allergic Contact Dermatitis of the Scalp Associated With Scalp Applied Products: A Systematic Review of Topical Allergens. Dermatitis. 2022 Mar 22.
PULSED DYE LASER AND HAIR LOSS IN INFANTILE HEMANGIOMAS
Yang et al (starts at 19:56). Risk factors of long-term alopecia after pulsed-dye laser treatment for infantile scalp hemangiomas: A retrospective study. J Dermatol. 2022 Apr 5.
Feldstein S et al. Can long-term alopecia occur after appropriate pulsed-dye laser therapy in hair-bearing sites? Pediatric dermatologists weigh in. Dermatol Surg. 2015 Mar;41(3):348-51.
ORAL PIGMENTATION FROM HYDROXYCHLOROQUINE
Silva PUJ et al (starts at 31:26). Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review. Medicine (Baltimore). 2022 Mar 18;101(11):e29044.
PERMANENT CHEMOTHERAPY INDUCED ALOPECIA
Lyakhovitsky A et al (starts at 37:38). Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplantation treated with low-dose oral minoxidil. JAAD Case Rep. 2022 Feb 17;22:64-67.
Vano-Galvan S et al. Safety of low dose oral minoxidil for hair loss: A multicenter study of 1404 patients. JAAD 2021; 84: 1644-51.
Sanabria B et al. Adverse effects of low dose oral minoxidil for androgenetic alopecia in 435 patients. JAAD 2021; 84: 1175-78.
Kolla et al (starts at 54:24). Permanent chemotherapy-induced alopecia presenting with erosive pustular dermatosis-like retention hyperkeratosis. JAAD Case Rep. 2022 Jan 6;21:77-79.
Yin et al (starts at 58:25). Dermatologist Awareness of Scalp Cooling for Chemotherapy-induced Alopecia. J Am Acad Dermatol. 2022 Mar 9;S0190-9622(22)00386-3
STUDIES REFERENCED
FRONTAL FIBROSING ALOPECIA & REPIGMENTATION:
Barreto TM et al (starts at 3:18). Atypical frontal fibrosing alopecia presentation in a male patient associated with spontaneous reversal of canities. J Eur Acad Dermatol Venereol. 2022 Mar 12
Defo D et al Repigmentation pilaire enbordure d’une alopecie frontale fibrosante. [Hair darkening close to a patch of frontal fibrosing alopecia]. Ann Dermatol Venereol 2006;133: 799–801
Pastor-Nieto et al. Localized grey hair repigmentation (canities reversal) in patients with frontal fibrosing alopecia. J Eur Acad Dermatol Venereol 2021; 35: e408–e410.
COSMETIC SURGERY AND RISK OF FRONTAL FIBROSING ALOPECIA:
Pham et al (starts at 9:00). The Association of Frontal Alopecia with a History of Facial and Scalp Surgical Procedures. Skin Appendage Disord. 2022 Jan;8(1):13-19.
Kossard and Shiell. Frontal fibrosing alopecia developing after hair transplantation for androgenetic alopecia. Int J Dermatol. 2005 Apr;44(4):321-3.
Chiang YZ et al. Lichen planopilaris following hair transplantation and face-lift surgery Br J Dermatol. 2012 Mar;166(3):666-370.
HAIR TRANSPLANT SURGERY FOR PATIENTS WITH FFA:
Vano-Galvan S et al (starts at 14:30). Hair transplant in frontal fibrosing alopecia: A multicenter review of 51 patients. J Am Acad Dermatol. 2019 Sep;81(3):865-866.
Arasu et al (starts at 22:13). Scalp reduction surgery does not reactivate frontal fibrosing alopecia: A case report. Dermatol Ther. 2022 Mar 16;e15451.
LICHEN PLANOPILARIS AND CHECKPOINT INHIBITORS
Garcia-Melendo C et al (starts at 38:59). Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatol Ther. 2022 Feb 17;e15388.
Uthayakumar AK et al. Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. Australas J Dermatol. 2021 Aug;62(3):403-406.
Cogen et al. Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. JAAD Case Rep . 2018 Jan 16;4(2):132-134.
Dominguez-Santas M et al. Avelumab-induced lichen planopilaris, a novel association. Int J Dermatol. 2021 Oct;60(10):e414-e416.
REFERENCES CITED IN THIS EPISODE (and TIME STAMP)
TELOGEN EFFLUVIUM
Monari et al (starts at 4:20). Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication. J Clin Med. 2022 Feb 24;11(5):1234.
Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
Guarnieri G et al (starts at 9:07). Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. Ann Med. 2022;54(1):869-874.
Wong-Chew RM et al (starts at 13:11). Symptom cluster analysis of long COVID-19 in patients discharged from the Temporary COVID-19 Hospital in Mexico City. Ther Adv Infect Dis. 2022 Jan 11;9:20499361211069264.
Fernandez-de-Las-Penas et al. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J Clin Med. 2022 Jan 14;11(2):413.
Ali MD (starts at 18:49). Proton pump inhibitors' use and risk of iron deficiency anaemia: a systematic review and meta-analysis. Curr Rev Clin Exp Pharmacol. 2022 Mar 7.
TRICHOTILLOMANIA AND PEDIATRIC EMOTIONAL HEALTH
Wang et al (starts at 24:29). Trichotillomania occurs during the COVID-19 pandemic in an adolescent. World J Pediatr. 2022 Feb 28;1-2.
Saunders NR et al. Utilization of Physician-Based Mental Health Care Services Among Children and Adolescents Before and During the COVID-19 Pandemic in Ontario, Canada. April 2022 JAMA Pediatrics.2022 Apr 1;176(4):e216298.
Racine N et al. Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis JAMA Pediatr. 2021;175(11):1142-1150.
Pathoulas et al. Cross-sectional survey examining skin picking and hair pulling disorders during the COVID-19 pandemic. J Am Acad Dermatol. 2021 Mar;84(3):771-773.
Öner Ü. Children with trichotillomania in COVID-19 outbreak. J Cosmet Dermatol. 2021;20(7):1967–8.
TINEA CAPITIS
Salah NB et al (starts at 31:19). Erythema nodosum in patients with kerion of scalp. Clin Exp Dermatol. 2021 Dec;46(8):1577-1578.
Blake T et al. Erythema nodosum - a review of an uncommon panniculitis. Dermatol Online J. 2014 Apr 16;20(4):22376.
Kumar P and Pandhi D (starts at 41:09). Role of Trichoscopy in the Management of Tinea Capitis in Two Infants: A Case Report. J Cutan Aesthet Surg. Oct-Dec 2021;14(4):443-445.
STUDIES HIGHLIGHTED
ALOPECIA AREATA
King B et al (starts at 3:27). Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
Fenentinos P et al (starts at 16:24). Assessing the role of stressful life events in the induction and recurrence of alopecia areata: a case-control study. J Am Acad Dermatol. 2022 Mar 24;S0190-9622(22)00526-6.
Macbeth A et al (starts at 21:14). The associated burden of mental health conditions in alopecia areata: A population-based study in UK primary care. Br J Dermatol. 2022 Feb 14.
Senna M et al (starts at 29:06). Predictors of Quality of Life in Patients with Alopecia Areata. J Invest Dermatol 2022 Mar 21;S0022-202X
ANDROGENETIC ALOPECIA
Ghafoor R et al (starts at 39:15). Association of androgenetic alopecia and severity of coronavirus disease 2019. J Cosmet Dermatol. 2022 Mar;21(3):874-879.
Baghani M et al (starts at 40:57). Androgenetic alopecia and COVID-19: Is there a clinical connection? J Cosmet Dermatol . 2022 Feb;21(2):420-425.
Veskovic D et al (starts at 42:04). Association of androgenetic alopecia with a more severe form of COVID-19 infection. Ir J Med Sci. 2022 Mar 23;1-6.
Recording of the Evidence Based Hair Podcast for the March 28, 2022 issue. STUDIES HIGHLIGHTED Trueb RM et al (starts at 3:27). Minoxidil-induced hypertrichosis in a breastfed infant. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e224-e225. Gangal et al (starts at 7:08). Mask-associated acquired trichorrhexis nodosa of the beard. JAAD Case Rep. 2022 Mar;21:101-102. Trueb RM et al. Prepubertal pattern hair loss (starts at 13:38) Clin Exp Dermatol. 2022 Jan;47(1):173-175.):24-30 Katayama S et al (starts at 17:00). Rapidly Progressive Hair Loss May Be the Only Sign of Syphilis. Am J Med 2022 Feb 22;S0002-9343(22)00130-9. Kolla et al (starts at 32:34). Dermatologists' knowledge of dermoscopic features in hair and nail disorders. J Eur Acad Dermatol Venereol. 2022 Feb 11. Rutnin S et al (starts at 37:32)). Variation of Hair Follicle Counts among Different Scalp Areas: A Quantitative Histopathological Study. Skin Appendage Disord. 2022 Jan;8(1):24-30. Xie et al (starts at 42:27). Hair shaft miniaturization causes stem cell depletion through mechanosensory signals mediated by a Piezo1-calcium-TNF-α axis. Cell Stem Cell 2022 Jan 6;29):
STUDIES HIGHLIGHTED
FFA STUDIES
Dubin C et al (starts at 2:50). Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
Starace et al (starts at 12:31). Clinical and Dermoscopic Approaches to Diagnosis of Frontal Fibrosing Alopecia: Results From a Multicenter Study of the International Dermoscopy Society. Dermatol Pract Concept. 2022 Jan 1;12(1):e2022080
Rayinda T et al (starts at 17:25). Clinical characteristics of male frontal fibrosing alopecia: a single-centre case series from London, UK. Br J Dermatol. 2022 Jan;186:195-197
LPP STUDIES
Moussa A et al (starts at 21:51). Treatment of lichen planopilaris with baricitinib: A retrospective study. J Am Acad Dermatol. 2022 Feb 21;S0190-9622(22)00338-3
Mostafa N et al (starts at 25:24). Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis. J Dermatolog Treat . 2022 Feb;33(1):369-372.
FOLLICULITIS DECALVANS STUDIES
Iorizzo M et al (starts at 27:25). Refractory folliculitis decalvans treated with adalimumab: a case series of 23 patients. J Am Acad Dermatol 2022 Mar 1;S0190-9622(22)00358-9.
CCCA STUDIES
Roche FC et al (starts at 33:01). Association of type 2 diabetes with central centrifugal cicatricial alopecia: A follow-up study. J Am Acad Dermatol. 2022 Mar;86(3):661-662.
Collins MS et al (starts at 37:45). Increased risk of vitamin D deficiency and insufficiency in Black patients with central centrifugal cicatricial alopecia. J Am Acad Dermatol . 2022 Feb 15;S0190-9622(22)00272-9.
Powe et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013 Nov 21;369(21):1991-2000.
Brown L et al. The vitamin D paradox in Black Americans: a systems-based approach to investigating clinical practice, research, and public health - expert panel meeting report. BMC Proc . 2018 May 9;12(Suppl 6):6.
STUDIES HIGHLIGHTED IN THIS EPISODE
TELOGEN EFFLUVIUM
Lytvyn et al (starts at 2:15). Comparing the frequency of isotretinoin-induced hair loss at
STUDIES HIGHLIGHTED IN THIS EPISODE
Qui Y et al (starts at 2:41). Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
Gupta AK et al (starts at 8:38). Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743
Plante J (starts at 23:13). Perifollicular inflammation and follicular spongiosis in androgenetic alopecia. J Am Acad Dermatol 2022Feb;86(2):437-438.
Qiu et al (starts at 28:04). Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients. Lasers Med Sci. 2022
Yale K et al (starts at 33:53). A year in review: A cross-sectional study of alopecia areata and risk of COVID-19 infection, hospitalization, and mortality from March 2020 -February 2021 Int J Dermatol. 2022 Mar;61(3):e81-e83.
Lee MM (starts at 38:10). Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity? Int J Dermatol. 2022 Feb
Bardazzi et al (starts at 39:04). New insights on alopecia areata during COVID-19 pandemic: when infection or vaccination seems to play a role. J Cosmet Dermatol. 2022 Feb 188.
Scollan M et al (starts at 41:08). Alopecia areata after SARS-CoV-2 vaccination JAAD Case Rep. 2022 Feb;20:1-5.
Harries M et al (starts at 43:42). The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022 Feb;186(2):257-265.
Gutierrez Y et al (starts at 49:38). Alopecia areata in the United States: a ten-year analysis of patient characteristics, comorbidities, and treatment patterns. Dermatol Online J. 2021 Oct 15;27(10)
STUDIES HIGHLIGHTED IN THIS EPISODE
Korbi M et al (starts at 1:58). Topical minoxidil-induced paresthesia. Dermatol Ther. 2022 Jan 20;e15328.
Panigrahi M et al (starts at 9:37). A recent surge of doxycycline-induced pill esophagitis during the corona virus disease 2019 (COVID-19) pandemic. Indian J Gastroenterol Jan 2022
Panigrahi M et al (starts at 14:45). A recent surge of doxycycline-induced pill esophagitis during the corona virus disease 2019 (COVID-19) pandemic. Indian J Gastroenterol Jan 2022
Bommareddy et al (starts at 18:48). Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatol 2022 Feb 9
Ytterberg SR et al (starts at 25:13). Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi:
Snast I et al (starts at 37:45). Paradoxical Hypertrichosis Associated with Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-analysis Am J Clin Dermatol 2021 Sep;22(5):615-624
STUDIES HIGHLIGHTED IN THIS EPISODE FRONTAL FIBROSING ALOPECIA STUDIES Maghfour J et al (starts at 3:09). The Association between Frontal Fibrosing Alopecia, Sunscreen, and Moisturizers: A Systematic Review with a Meta-Analysis. J Am Acad Dermatol. 2022 Jan 21 (online). Sun et al (starts at 6:36). Characterization and Treatment of Prominent Facial Vasculature in the Setting of Frontal Fibrosing Alopecia J Am Acad Dermatol 2022 Jan 5; (online) Lobato-Berezo et al (starts at 11:05). Frontal fibrosing alopecia in men: A multicenter study of 39 patients. J Am Acad Dermatol. 2022 Feb;86(2):481-484. Bernardez C et al (starts at 13:57). Beard loss in men with frontal fibrosing alopecia. J Am Acad Dermatol. 2022 Jan;86(1):181-183. LICHEN PLANOPILARIS STUDIES Gardellini A et al (starts at 20:26). Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy. J Oncol Pharm Pract. 2022 Jan 17 (online) Lahouel et al. Nilotinib-induced lichen planopilaris. Int J Dermatol. 2022 Jan;61(1):e37-e38. CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA STUDIES Jamerson et al (starts at 30:00). Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan 10 FOLLICULITIS DECALVANS STUDIES Moussa A et al (starts at 34:58). Successful treatment of folliculitis decalvans with baricitinib: A case series. Australas J Dermatol. 2022 Jan 22.
STUDIES REFERENCED IN THIS EPISODE
TELOGEN EFFLUVIUM - HAIR LOSS FOLLOWING COVID 19
STUDY 1 (starts at 3:09 ): Lopez-Leon S et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021 Jan 30;2021.01.27.21250617.
STUDY 2 (starts at 4:47): Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
STUDY 3 (starts at 10:32 ): Fernandez-de-Las-Penas et al. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J Clin Med. 2022 Jan 14;11(2):413.
TELOGEN EFFLUVIUM IN CHILDREN
STUDY 4 (starts at 12:45 ): Thomas et al. Single Centre Retrospective Review ofNutritional Deficiencies Associated With Telogen Effluvium in the Paediatric Population in Canada. J Cut Med Surg Jan 2022 (online)
TRICHOTILLOMANIA
STUDY 5 (starts at 18:44) : Moattari et al. Adverse psychocutaneous effects of prescription stimulant use and abuse: A systematic review. J Dtsch Dermatol Ges. 2022 Jan;20(1):7-15.
STUDY 6: (starts at 23:12); Vaccaro et al. Erosive pustular dermatosis of the scalp as local complication of trichotillomania. J Cosmet Dermatol. 2022 Jan 8. 2022 Jan 8
TINEA CAPITIS
STUDY 7 (starts at 27:51): Friedland et al. Epidemiologic features and risk of scarring in pediatric patients with kerion celsi. Pediatr Dermatol. 2022 Jan 13. doi: 10.1111/pde.14916. Online ahead of print.
REFERENCED STUDIES FOR ANDROGENETIC ALOPECIA
Silva et al (starts at 1:10). Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair Loss: 0.25 mg versus 1 mg. Journal of the American Academy of Dermatology; Online Jan 2022.
Therianou et al (starts at 3;18). How Safe Is Prescribing Oral Minoxidil in Patients Allergic to Topical Minoxidil? Journal of the American Academy of Dermatology. J Am Acad Dermatol Feb 2022.
James JF et al. (starts at 4:51) Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review. J Am Acad Dermatol. Feb 2022
Plante et al (starts at 8:05). The Need for Potassium Monitoring in Women on Spironolactone for Dermatologic Conditions. J Am Acad Dermatol. 2022 Jan 21 Online;S0190-9622(22)00081-0.
Özcan D (starts at 10:59). Pediatric androgenetic alopecia: a retrospective review of clinical characteristics, hormonal assays and metabolic syndrome risk factors in 23 patients An Bras Dermatol. 2022 Jan 12; online
Zong et al (starts at 14:40). Prevalence of ocular anomalies is increased in women with polycystic ovary syndrome-exploration of association with PAX6 genotype. Ophthalmic Genetics. 2022 Jan 11;1-4. Online
Deng et al (starts at 15:51). Androgen receptor mediated paracrine signaling induces regression of blood vessels in the dermal papilla in androgenetic alopecia. J Invest Dermatol. Jan 2022 online
Li K et al (starts at 18:48). Association of fibrosis in the bulge portion with hair follicle miniaturization in androgenetic alopecia. J Am Acad Dermatol 2022; Jan;86(1):213-215.
REFERENCED STUDIES FOR ALOPECIA AREATA
Di Fillipo et al (starts at 22:14). Efficacy of 308-nm excimer therapy in alopecia areata: a retrospective study with long-term follow-up Photodermatol Photoimmunol Photomed 2022 Jan 21. online.
Ting H-C et al (starts at 25:30). Association between alopecia areata and retinal diseases: A nationwide population-based cohort study. J Am Acad Dermatol 2021 Nov 1; online
Abdelkader HA et al (starts at 26:24). Histone deacetylase 1 in patients with alopecia areata and acne vulgaris: An epigenetic alteration. Australas J Dermatol. 2022 Jan 25. Online.
Introduction to the Evidence Based Hair Podcast, a podcast highlighting the latest research in hair loss. Welcome to Season 1!